- Host-pathogen interactions
- Viral and bacterial vaccine and therapeutic development
- Pathogenesis of viral and bacterial pathogens
Dr. Hogan began his 27-year scientific career studying host-pathogen interactions during his graduate studies, which focused on immune responses to viral infection in teleosts. After receiving his doctoral degree, he joined the laboratory of Dr. David Woodland at St. Jude Children’s Research Hospital, where his research focused on cell-mediated immune responses mediated by bacterial superantigens. After moving with Dr. Woodland to the Trudeau Institute, he received an individual National Research Service Award from NIH-NIAID to study T cell responses against respiratory virus pathogens (e.g. influenza and paramyxoviruses). Upon joining the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick, Maryland as a Principal Investigator, Dr. Hogan engaged in the development of vaccines for protection against both Marburg and Ebola viruses in mouse and nonhuman primate (NHP) models of disease under BSL-4 containment. He continued studying immune responses against Ebola virus proteins and initiated animal model development and vaccine development for SARS-Coronavirus (SARS-CoV) vaccines after transitioning to the Southern Research Institute. Since arriving at the University of Georgia 13 years ago, his laboratory has continued to examine immune responses induced by vaccination and infections with bacterial and viral pathogens under BSL-2 and BSL-3 containment with over $22,000,000 in extramural funding from multiple sources as both P.I. and Co-P.I. During the last several years, he has worked closely with Dr. Eric Lafontaine to develop animal models and vaccines for Burkholderia mallei and pseudomallei in mice, NHPs, and horses.
PhD (1998) University of Mississippi Medical Center
BS (1992) Belhaven College
Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ , García-Sastre A, Compans R, Pulendran B. Programming the magnitude and persistence of antibody responses with innate immunity. Nature, 470:543-547, 2011.
Wong G, Richardson JS, Pillet S, Patel A, Qiu X, Alimonti J, Hogan J , Zhang Y, Takada A, Feldmann H, Kobinger GP. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci. Transl. Med., 4, 158ra146, 2012.
Li Z, Mooney A, Gabbard JD, Gao X, Xu P, Place RJ, Hogan RJ , Tompkins SM, He B. Recombinant Parainfluenza Virus 5 Expressing HA Of Influenza A Virus H5N1 Protected Mice Against Lethal High Pathogenic Avian Influenza H5N1 Challenge. Journal of Virology, 87:354-362, 2013.
Xu P, Huang Z, Gao X, Michel FJ, Hirsch G, Hogan RJ , Sakamoto K, Ho W, Wu J, He B. Infection of mice, ferrets, and rhesus macaques with a clinical mumps virus isolate. Journal of Virology, 87:8158-8168, 2013.
Shaffer TL, Balder R, Buskirk SW, Hogan RJ , Lafontaine ER. Use of the Chinchilla Model to Evaluate the Vaccinogenic Potential of the Moraxella catarrhalis Filamentous Hemagglutinin-like Proteins MhaB1 and MhaB2. PLoS One, 8(7), 2013.
Lafontaine ER, Zimmerman SM, Shaffer TL, Michel F, Gao X, Hogan RJ. Use of a safe, reproducible, and rapid aerosol delivery method to study infection by Burkholderia pseudomallei and Burkholderia mallei in mice. PLoS One, 8(10), 2013.
Lafontaine ER, Balder R, Michel F, Hogan RJ. Characterization of an autotransporter adhesin protein shared by Burkholderia mallei and Burkholderia pseudomallei. BMC Microbiology, 14:92, 2014.
Jelesijevic T, Zimmerman SM, Harvey SB, Mead DG, Shaffer TL, Estes DM, Michel F, Quinn FD, Hogan RJ , Lafontaine ER. Use of the Common Marmoset to Study Burkholderia mallei Infection. PLoS One, 10(4), 2015.
Zimmerman SM, Michel F, Hogan RJ , Lafontaine ER. The Autotransporter BpaB Contributes to the Virulence of Burkholderia mallei in an Aerosol Model of Infection. PLoS One, 10(5), 2015.
Li Z, Hung C, Paterson RG, Michel F, Fuentes S, Place R, Lin Y, Hogan RJ , Lamb RA, He B. Type II integral membrane protein, TM of J paramyxovirus promotes cell-to-cell fusion. PNAS, 112(40), 12504-12509, 2015.
Aschenbroich SA, Lafontaine ER, Hogan RJ. Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches. Expert Rev Vaccines, Apr 20:1-19, 2016.
Zimmerman SM, Long ME, Dyke JS, Jelesijevic TP, Michel F, Lafontaine ER, Hogan RJ. Use of Immunohistochemistry to demonstrate in vivo expression of the Burkholderia mallei virulence factor BpaB during experimental glanders. Veterinary Pathology, Mar/Nov 55(2), 2018.
Zimmerman SM, Long ME, Dyke JS, Jelesijevic TP, Michel F, Lafontaine ER, Hogan RJ*. Use of Immunohistochemistry to demonstrate in vivo expression of the Burkholderia mallei virulence factor BpaB during experimental glanders. Veterinary Pathology, Mar/Nov 55(2), 2018.
Zimmerman SM, Dyke J, Jelesijevic TP, Michel F, Lafontaine ER, Hogan RJ. Antibodies against in vivo-expressed antigens are sufficient to protect against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei. Infection and Immunity, Jul 19:85, 2017.
Hogan RJ and Lafontaine ER. Antibodies Are Major Drivers of Protection against Lethal Aerosol Infection with Highly Pathogenic Burkholderia spp. mSphere, Jan2;4, 2019.
Wu H, Fan Z, Brandsrud M, Meng Q, Bobbitt M, Regouski M, Stott R, Sweat A, Crabtree J, Hogan RJ, Tripp RA, Wang Z, Polejaeva IA, Sullivan EJ. Generation of H7N9-specific human polyclonal antibodies from a transchromosomic goat (caprine) system. Nature Scientific Reports, Jan 23;9(1):366, 2019.